National University Cancer Institute, Singapore and MiNA Therapeutics announce initiation of a Phase 1 clinical study of MTL-CEBPA in combination with first-line standard of care in advanced liver cancer 01 December, 2021 MiNA Therapeutics highlights clinical data supporting the further development of MTL-CEBPA as an anti-cancer immunotherapy 12 November, 2021 MiNA Therapeutics Expands Senior Leadership Team With Four New Hires to Support Next Phase of Growth 12 Oct, 2021 MiNA Therapeutics announces equity investment from Lilly 06 July, 2021


Harnessing the innate mechanism of gene activation, MiNA Therapeutics’ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases.


Small activating RNAs are an entirely new class of medicines with potential to offer transformational benefits to patients across a wide range of diseases.


We have developed a systematic approach to take new saRNA medicines from an idea to patients in a clinical trial in just 2 years.


Driving our platform are a group of passionate scientists, drug developers, doctors and entrepreneurs shaped by experience in oligonucleotide therapeutics, oncology and immunology.

By continuing to use this site you are agreeing only to the use of cookies that are strictly necessary for the running of our website. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.